Navigation Links
MabVax Therapeutics Closes $5.25 Million Financing with Numoda Capital Innovations, Burrill Capital Fund IV, and RTP Venture Fund
Date:11/20/2012

SAN DIEGO, Nov. 20, 2012 /PRNewswire/ -- MabVax Therapeutics, Inc., a privately held clinical stage biotechnology company focused on the development of proprietary immunotherapies to address the unmet medical need of preventing recurrent cancer, today announced the closing of the first tranche in their Series B financing.  Numoda Capital Innovations led the round and was joined by existing investors Burrill Capital Fund IV and RTP Venture Fund for an aggregate investment of $5.25 million. The additional capital will allow MabVax to continue the development of its phase 2 vaccine aimed at preventing recurrent sarcoma and its 5B1 antibody program targeting metastatic pancreatic cancer.

The phase 2 clinical trial of the sarcoma vaccine has reached the targeted enrollment of 134 stage IV sarcoma patients in a randomized, multicenter, double-blind study of a vaccine specifically developed to elicit a targeted antibody response intended to kill residual circulating cancer cells and micrometastases that can cause recurrent sarcoma. The primary efficacy result of progression free survival (PFS) is expected to be reported in the second half of 2013.  The financing provides MabVax access to Numoda's advanced and patented clinical trial information technologies and management systems. These technologies will enable MabVax to move through the clinical trial process efficiently while providing visibility for reporting early assessments and timely trial results.  

The financing will also allow MabVax to continue development of the 5B1 antibody program targeting an antigen that is widely expressed in pancreatic cancer. The company has discovered and completed preclinical testing of a fully human IgG1 antibody with high affinity and exquisite specificity for the antigen and remarkable in vivo efficacy in a series of pancreatic and other cancer cell lines in SCID mice. MabVax is planning to begin GMP manufacturing of this antibody early in 2013
'/>"/>

SOURCE MabVax Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Cystic Fibrosis Foundation Therapeutics Announces $58 Million CF Drug Discovery Agreement with Pfizer
2. Echo Therapeutics Hires Daniel Sunday as Vice President of Manufacturing and Global Supply Chain
3. Caliber and ImmunGene Launch Valor Biotherapeutics, a Joint Venture to Develop Antibody-Interferon Fusion Therapeutics to Treat Cancers
4. Echo Therapeutics Chosen to Present at the 12th Annual Diabetes Technology Meeting
5. Immunomic Therapeutics Begins Phase I Japanese Red Cedar JRC-LAMP-Vax Vaccine Safety Study
6. Stemline Therapeutics Lead Clinical Candidate SL-401 Induces a Complete Response in a Patient with a Drug-Refractory Plasmacytoid Dendritic Cell Neoplasm
7. Echo Therapeutics Announces Third Quarter 2012 Financial Results
8. Orexigen Therapeutics Reports Financial Results for the Third Quarter Ended September 30, 2012
9. Particle Sciences Develops Novel Ocular Formulation for Eyeon Therapeutics
10. Halozyme Therapeutics To Present At The Lazard Capital Markets 9th Annual Healthcare Conference
11. Novelos Therapeutics Closes $2 Million Private Placement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)...   MedeAnalytics today unveils Revenue Integrity, ... visibility to a provider,s "mid-cycle" to optimize revenue ... Powered by the industry,s leading big data platform, ... between patient access and the business office where ... revenue capture, minimize audit risk and prepare providers ...
(Date:9/17/2014)... --  myMatrixx, a pharmacy and ancillary medical benefit manager for workers, ... has awarded myMatrixx with a "Best Places to Work ... row. Best Places to Work is ... Best Companies Group.  The competition, which involves months of ... insurance industry companies with at least 25 employees in ...
(Date:9/17/2014)... MADISON, Tenn. , Sept. 17, 2014 ... be; these infections are not only uncomfortable, they,re often ... best-laid social plans. pH-D Feminine Health Support ( http://ph-defense.com ... vaginal health. It is an all-natural, homeopathic product. ... the most common symptoms of vaginal infection. In many ...
Breaking Medicine Technology:MedeAnalytics Unveils New Revenue Integrity Solution to Support the Transition to Value-Based Healthcare 2MedeAnalytics Unveils New Revenue Integrity Solution to Support the Transition to Value-Based Healthcare 3myMatrixx Honored with "Best Places to Work in Insurance" Award 2New Product from Vireo Systems: pH-D Feminine Health Support 2
... FRANCISCO, Calif., Aug. 25, 2011 Rigel Pharmaceuticals, Inc. ... M. Gower, chairman and chief executive officer, and Ryan ... Rigel, will present at two separate investor conferences in ... Healthcare Conference 2011Date: Thursday, September 8th at 10:20 a.m. ...
... Nutrastar International Inc. (OTCBB: NUIN; "Nutrastar" or the "Company"), ... Chinese Medicine ("TCM") consumer products, today announced that its ... under which Nutrastar may repurchase up to US$5 million ... 12 months. Under the program, the ...
Cached Medicine Technology:Nutrastar Announces Adoption of Share Repurchase Program 2Nutrastar Announces Adoption of Share Repurchase Program 3
(Date:9/18/2014)... Lake City, Utah (PRWEB) September 18, 2014 ... Now Spoonful of Comfort, an online food delivery service provider, ... , New Country Fresh Tomato Basil soup is a nod ... begins, of course, with a tangy tomato base, then Spoonful ... asiago and parmesan cheeses. A flashback to childhood has never ...
(Date:9/18/2014)... 2014 Computer Resources of America, Inc. ... New York City, has been awarded a contract to ... retailer with stores in over 150 countries. The services ... CRA being the retailer’s dispatch arm handling all IT ... Ramnarayan, Chief Executive Officer of CRA said, “We are ...
(Date:9/18/2014)... NY (PRWEB) September 18, 2014 ... which have special functions of adjusting human body ... have won great popularity with a variety of ... health food in China reached RMB187.4 billion, up ... 22.1% during 2006-2013. , View Full Report at ...
(Date:9/18/2014)... MA (PRWEB) September 18, 2014 ... its team and surgeon partners in Less Exposure ... joining SpineFrontier, Tamara authored an extensive education curriculum ... a Masters in Science in Organizational Leadership, and ... industries for eleven years. Bringing her to the ...
(Date:9/18/2014)... Dr. Suzaunna Clark, Psychologist, Life Coach and ... has to be seen to be believed and 2- ... to be used. Together, both lead to hearts that ... to do both. , Dr. Clark offers ... Hearts system, which provides professional guidance on dealing with ...
Breaking Medicine News(10 mins):Health News:An Old Classic Brings New Soup Delivery Options to Spoonful of Comfort 2Health News:CRA Awarded Managed Support Contract for Global Retailer 2Health News:China Health Food Industry Size 2014 Market Analysis, Growth, Trends and Forecast Report 2017: MarketResearchReports.biz 2Health News:China Health Food Industry Size 2014 Market Analysis, Growth, Trends and Forecast Report 2017: MarketResearchReports.biz 3Health News:China Health Food Industry Size 2014 Market Analysis, Growth, Trends and Forecast Report 2017: MarketResearchReports.biz 4Health News:SpineFrontier Inc. Makes Bold Move to Expand Its Internal Training Team to Collaborate With The LESSociety’s Less Exposure Surgery® University To Educate Surgeons. 2Health News:Suzaunna-Where Life! Happens Announces the Launch of Healing Hearts 2Health News:Suzaunna-Where Life! Happens Announces the Launch of Healing Hearts 3
... June 11 Orexigen(R) Therapeutics, Inc. (Nasdaq: ... of obesity, today announced the licensing of certain intellectual ... IP position underlying Contrave, its lead product candidate for ... agreement with GSK complements the IP foundation of Contrave, ...
... - Members of Congress Seek to Stem Growing Healthcare Coverage Shortfalls ... has introduced a bill, S. 1221, "The Medicare Prompt Pay ... introduced in the U.S. House of Representatives and currently has 45 ... Senators Arlen Specter (D-PA) and Pat Roberts (R-KS). The bill is ...
... WASHINGTON, June 11 A call for participants ... a national certification for medical interpreters. The National ... as an independent 501(c)3 non-profit certification entity, will ... ensure that the certification process is credible, transparent, ...
... Pharmaceuticals, Inc. (Nasdaq: TSPT ) announced today that ... company that it should expect to receive formal notice of ... new drug application (NDA) for Intermezzo (R) (zolpidem tartrate ... assigned a Prescription Drug User Fee Act (PDUFA) date of ...
... Help Grieving Children and Families , , CAMP HILL, ... 185 volunteers on Monday, June 15 at the Radisson Penn ... 6,500 hours - an average of nearly 35 hours each ... adolescents and their families at the Caring Place facility in ...
... Canada, June 11 Xenon today announced a strategic ... to discover and develop novel small molecule candidates for ... "We are very excited to be collaborating with Merck ... diseases," said Simon Pimstone, President and CEO of Xenon. ...
Cached Medicine News:Health News:Orexigen(R) Therapeutics Announces In-Licensing of Key Patents to Further Strengthen its Intellectual Property Estate for Contrave(R) 2Health News:Orexigen(R) Therapeutics Announces In-Licensing of Key Patents to Further Strengthen its Intellectual Property Estate for Contrave(R) 3Health News:Senate Bill to Protect Patients' Healthcare by Amending Medicare Coverage 2Health News:Senate Bill to Protect Patients' Healthcare by Amending Medicare Coverage 3Health News:Public Call for Participation on National Board of Certification for Medical Interpreters 2Health News:Public Call for Participation on National Board of Certification for Medical Interpreters 3Health News:Transcept Pharmaceuticals Announces Expected FDA Extension of Regulatory Review Period for Intermezzo(R) 2Health News:Transcept Pharmaceuticals Announces Expected FDA Extension of Regulatory Review Period for Intermezzo(R) 3Health News:Transcept Pharmaceuticals Announces Expected FDA Extension of Regulatory Review Period for Intermezzo(R) 4Health News:Highmark Caring Place To Honor Midstate Volunteers 2Health News:Highmark Caring Place To Honor Midstate Volunteers 3Health News:Xenon Enters Cardiovascular Disease Collaboration With Merck & Co., Inc. 2
... The Leica TP1020 product family are ... a perfect combination of approved technology with ... processing and maximum safety for tissues at ... engineering design based on proven precision mechanics ...
The HMP300 Histo Pro delivers all the features and benefits that conventional tissue processing have to offer....
... electronic, motorized rotary microtomes ... applications of paraffin, semi-thin ... specimens in clinical, research, ... instruments display extra-ordinary ergonomic ...
... RM2235 is a robust rotary microtome ... biological specimens embedded in paraffin. The ... micrometer feed system ensures premium quality ... sectioning harder tissues. The RM2235 is ...
Medicine Products: